Veru (NASDAQ:VERU – Get Free Report) and Flora Growth (NASDAQ:FLGC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Earnings and Valuation
This table compares Veru and Flora Growth”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veru | N/A | N/A | -$22.73 million | ($2.20) | -1.06 |
| Flora Growth | $57.61 million | 0.17 | -$15.91 million | ($32.49) | -0.29 |
Institutional and Insider Ownership
47.2% of Veru shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 2.3% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Veru and Flora Growth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veru | N/A | -119.51% | -74.98% |
| Flora Growth | -32.03% | -64.02% | -34.46% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Veru and Flora Growth, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veru | 1 | 0 | 3 | 0 | 2.50 |
| Flora Growth | 1 | 0 | 1 | 0 | 2.00 |
Veru presently has a consensus price target of $22.50, indicating a potential upside of 861.54%. Flora Growth has a consensus price target of $30.00, indicating a potential upside of 222.23%. Given Veru’s stronger consensus rating and higher possible upside, equities analysts plainly believe Veru is more favorable than Flora Growth.
Risk & Volatility
Veru has a beta of -1.42, suggesting that its stock price is 242% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500.
Summary
Veru beats Flora Growth on 7 of the 13 factors compared between the two stocks.
About Veru
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
About Flora Growth
Flora Growth Corp., together with its subsidiaries, engages in the growth, cultivation, and development of medicinal cannabis and medicinal cannabis derivative products worldwide. It operates through three segments: House of Brands, Commercial and Wholesale, and Pharmaceuticals. The company cultivates, processes, and supplies medicinal-grade cannabis flower, and cannabis derived medical and wellness products. It also offers food and beverage, nutraceuticals, cannabis accessories and technology, personal care, and wellness; cannabidiol (CBD) derived products, such as gummies, topicals, tinctures, and vape products; cannabis consumption accessories, personal storage, and travel accessories for the vape and dry herbs. In addition, the company manufactures and distributes pharmaceutical goods and medical cannabis products to treat a variety of health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants. The company sells its products under the JustCBD, Vessel, and Phatebo brands. Flora Growth Corp. was incorporated in 2019 and is based in Fort Lauderdale, Florida.
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
